GLIOBLASTOMA MULTIFORME

This early-phase study tests a modified virus designed to attack brain tumor cells that have come back or grown despite previous treatment. About 62 adults with certain types of brain cancer will receive the virus directly into the tumor, sometimes with a drug to boost the immune…

This early-phase study tests a new drug called DSP-0390 in 39 adults whose high-grade glioma (a fast-growing brain cancer) has come back after prior treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be…

This early-phase study tests whether adding the experimental drug S-Gboxin to standard radiation and chemotherapy can help people with glioblastoma or diffuse midline glioma, two aggressive brain cancers. About 10 participants whose tumors have returned or worsened will receive t…

This study tests a drug called ACP-196 (acalabrutinib) in adults whose glioblastoma brain tumor has come back after standard treatment. The goal is to see if the drug can shrink or control the tumor. About 24 participants will receive the drug, and their response will be measured…

This study tests whether adding high-dose vitamin C to the usual treatment (radiation and chemotherapy) can help adults with a newly diagnosed, aggressive brain tumor called glioblastoma live longer. About 90 participants will receive the vitamin C infusions alongside standard ca…

This study tests whether giving a higher radiation dose to a specific brain area (the subventricular zone) alongside standard radiation and chemotherapy can delay glioblastoma from coming back. About 60 adults with newly diagnosed glioblastoma will be randomly assigned to receive…

This study tests whether adding an experimental drug called NanO2 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. The drug is designed to deliver more oxygen to the tumor, which may make radiation work better. …

This early-phase trial tests a new treatment called Temferon for glioblastoma, a fast-growing brain cancer. It uses a patient's own blood stem cells, modified to deliver an immune-boosting protein (interferon) directly to the tumor. The study enrolls up to 27 people whose tumors …

This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…

This early-phase trial tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can boost the immune system's attack on glioblastoma, an aggressive brain cancer. About 63 patients with recurrent glioblastoma will receive the drugs or a placebo before…

This early-stage trial tests a drug called AZD1390 combined with radiation therapy in people with a fast-growing brain tumor (grade 4 glioma). About 97 participants with either new or returning tumors will receive the drug to see how well it reaches the tumor and if it helps cont…

This early-stage study tests whether adding high-dose vitamin C and a special iron drug (ferumoxytol) to standard radiation and chemotherapy can help adults with a newly diagnosed aggressive brain tumor called glioblastoma. The main goal is to find a safe dose of the iron drug. T…

This study tests whether adding an experimental drug called BPM31510 (with vitamin K1) to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 50 adults will receive the combination, and researchers will track ho…

This early-phase study tests a cancer vaccine called SurVaxM in 35 children with brain tumors that have come back or are hard to treat. The vaccine is designed to teach the body's immune system to find and destroy tumor cells carrying a protein called survivin. The goal is to see…

This study was designed for children with a type of aggressive brain cancer (high-grade glioma) that has come back after initial treatment. It planned to test an experimental virus therapy, G207, injected directly into the tumor, along with a single dose of radiation. The goal wa…

This study tests whether adding the antiviral drug valganciclovir to standard treatment can help people with glioblastoma, an aggressive brain cancer. The drug targets a common virus (CMV) found in most of these tumors, which may make the cancer more aggressive. About 220 adults …

This early-stage trial tests the safety and best dose of a drug called APX005M in 32 children whose brain tumors have come back or are hard to treat, including a type of brain stem tumor called DIPG. The drug works by activating the immune system to attack cancer cells. The main …

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This program provides gallium maltolate, an experimental oral drug, to adults with glioblastoma that has come back or not responded to standard treatments. It is for patients who have run out of other options and may still benefit. The goal is to control the disease, not cure it.

This early-phase study tests a personalized cell therapy for adults with glioblastoma and children with high-grade gliomas. The treatment uses a patient's own immune cells, modified to target a protein called CD70 on tumor cells and to better navigate to the brain. The main goals…

This study looks at how well the drug ribociclib gets into brain tumors in people with recurrent high-grade glioma or meningioma. About 48 participants will take the drug before their scheduled tumor removal surgery. The goal is to measure drug levels in the blood, spinal fluid, …

This study tests whether adding the experimental drug LAM561 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 144 adults aged 18 to 75 will receive either LAM561 or a placebo alongside their usual treatmen…

This trial tests a device implanted in the skull that uses ultrasound to temporarily open the blood-brain barrier, allowing chemotherapy drugs to reach brain tumors more effectively. About 57 adults with recurrent glioblastoma will receive this treatment after surgery to remove t…

This early-stage trial is testing whether combining two immunotherapy drugs with a precise, high-dose radiation treatment is safe and might help control recurrent glioblastoma, a very aggressive brain cancer. The study involves about 16 patients whose cancer has returned after in…